Clinical Trial

B4B Evolution Type II Hybrid Effectiveness-Implementation Trial

Study acronym: B4B Evolution
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Break4Brain Evolution is a school-based programme designed to help teachers incorporate brief, safe and inclusive movement activities into normal classroom routines. The study aims to examine both how the programme is adopted and delivered in real-world schools and whether it improves students' physical activity, attention, executive functions and academic achievement. This is a type II hybrid implementation-effectiveness study with two complementary components. The implementation component will examine the scale-up of Break4Brain Evolution across at least 50 preschool, primary and secondary schools in the Balearic Islands and mainland Spain. Information from school leaders, teachers and students will be used to assess programme reach, adoption, acceptability, feasibility, appropriateness, fidelity, adaptations and maintenance. The effectiveness component is an embedded cluster-randomized controlled trial conducted in six primary schools in Mallorca. Schools will be randomly allocated to either the Break4Brain Evolution programme or usual school practice, with three schools in each group. Two classrooms from each school, one grade 5 and one grade 6 classroom, will participate, resulting in an estimated sample of 300 students. Baseline assessments will be conducted in September 2026. Schools allocated to the intervention group will begin implementing Break4Brain Evolution in October 2026 and will use the programme during the academic year. Follow-up assessments will be conducted in February 2027, June 2027 and December 2027.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-07-31
Trial Details
NCT Number NCT07726732
Lead Sponsor University of the Balearic Islands
Collaborators: State Research Agency, Spain
Conditions Physical Activity, Sedentary Behavior, Cognition, Academic Acheivement
Enrollment 300 participants
Start Date 2026-09-15
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30